Immune checkpoint blockade (ICB) therapies targeting programmed cell death 1 (PD‐1) or ligand 1 (PD‐L1) and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) have demonstrated higher efficacy than standard therapies in several cancers [7]. Here, PDCD1 is linked to cancer.